What is Target-MRD^™?

Target-MRD^™ is a cutting-edge advanced test designed to help keep cancer in check. It is the only diagnostic test that detects even the smallest traces of cancer at the molecular level, known as Molecular Residual Disease (MRD).

How does it work?

Target-MRD^™ works by combining two powerful approaches:

Personalised Tumour-Informed Detection: Our tumour-informed testing focuses on genetic changes unique to your cancer, providing personalised monitoring to detect recurrence and track treatment effectiveness with precision.

Tumour-Agnostic Profiling: It looks broadly for signs of residual cancer, even if they aren't tied to a specific tumour type.

By using Target-MRD^™, your healthcare team can make more informed decisions about your treatment, monitor your progress closely, and act early if necessary to improve outcomes and ensure better care.

How does Target-MRD^™ help?

• Early Detection of Relapse: MRD enables detection of residual cancer cells at the molecular level before clinical or radiological relapse, allowing for earlier intervention and improved outcomes.
• Tailored Treatment Decisions: MRD status supports personalised treatment planning-helping clinicians decide whether to escalate, de-escalate, or discontinue the therapy based on the presence of molecular disease.
• Prognostic Indicator: MRD provides a key prognostic insight. Patients with undetectable MRD generally have better outcomes, while detectable MRD indicates a higher risk of recurrence.
• Guide to Post-Treatment Surveillance: MRD testing facilitates ongoing monitoring during remission, enabling timely adjustments in care and earlier detection of recurrence compared to conventional methods.